Is Sangani Hospital overvalued or undervalued?

As of 3 September 2025, Sangani Hospital's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 36.14, an EV to EBITDA ratio of 30.30, and a ROCE of 12.91%. In comparison to its peers, Sangani Hospital's PE ratio is significantly lower than that of Max Healthcare, which stands at 93.95, and higher than Apollo Hospitals at 70.78, both of which are classified as expensive.
Sangani Hospital's attractive valuation is further supported by its PEG ratio of 0.00, suggesting potential for growth without the corresponding high price. Despite a year-to-date return of -4.8%, the stock has outperformed the Sensex over the past year, with a return of 62.72% compared to the Sensex's -2.23%. This performance reinforces the notion that Sangani Hospital may be undervalued relative to its growth prospects and peer comparisons.